Cellebrite DI (NASDAQ:CLBT) Now Covered by Analysts at Lake Street Capital

Lake Street Capital began coverage on shares of Cellebrite DI (NASDAQ:CLBT - Free Report) in a research note released on Friday morning, Benzinga reports. The firm issued a buy rating and a $13.00 target price on the stock.

A number of other brokerages also recently issued reports on CLBT. Needham & Company LLC boosted their price target on Cellebrite DI from $13.00 to $13.50 and gave the company a buy rating in a report on Thursday, March 28th. Craig Hallum upped their target price on Cellebrite DI from $14.00 to $16.00 and gave the company a buy rating in a report on Monday, April 1st. Bank of America boosted their price objective on shares of Cellebrite DI from $12.00 to $13.00 and gave the company a buy rating in a research report on Monday, April 1st. Finally, William Blair upgraded shares of Cellebrite DI from a market perform rating to an outperform rating in a research report on Wednesday, March 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI currently has an average rating of Buy and a consensus price target of $12.42.

Cellebrite DI Price Performance

CLBT stock traded up $0.09 during trading hours on Friday, reaching $10.47. The stock had a trading volume of 503,973 shares, compared to its average volume of 952,165. The stock has a market capitalization of $2.15 billion, a PE ratio of -24.35, a price-to-earnings-growth ratio of 1.83 and a beta of 1.53. The stock has a 50-day simple moving average of $11.23 and a 200 day simple moving average of $9.19. Cellebrite DI has a fifty-two week low of $5.22 and a fifty-two week high of $12.50.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, February 15th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. Cellebrite DI had a positive return on equity of 173.14% and a negative net margin of 24.94%. The firm had revenue of $93.01 million during the quarter, compared to the consensus estimate of $85.43 million. On average, sell-side analysts forecast that Cellebrite DI will post 0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CLBT. IGP Investments G.P.L.P LP bought a new stake in shares of Cellebrite DI in the 4th quarter worth $182,619,000. Clal Insurance Enterprises Holdings Ltd purchased a new position in Cellebrite DI in the 3rd quarter worth about $50,270,000. Morgan Stanley lifted its stake in Cellebrite DI by 53,737.4% during the 4th quarter. Morgan Stanley now owns 2,144,884 shares of the company's stock valued at $9,352,000 after acquiring an additional 2,140,900 shares during the period. Ashford Capital Management Inc. bought a new stake in shares of Cellebrite DI in the fourth quarter worth approximately $12,913,000. Finally, Voss Capital LLC raised its holdings in shares of Cellebrite DI by 207.7% during the fourth quarter. Voss Capital LLC now owns 1,835,000 shares of the company's stock valued at $15,891,000 after purchasing an additional 1,238,580 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.